Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
at www.tipranks.com (Thu, 2-Apr 5:42 PM)
FDA Greenlights Armata’s AP-SA02 to Phase 3: First Bacteriophage Therapy to Advance in Complicated Staphylococcus aureus Bacteremia
Market Chameleon (Tue, 13-Jan 7:51 AM)
